type: insight tags: [specialty-pharma, gross-to-net, prescription-volume, revenue-quality, payer, net-revenue-per-rx] confidence: medium created: 2026-04-01 source: ARQT stock-analysis 2026-04 persona: atlas provenance: legacy source_analysis_path: null source_paragraph_quote: null source_transcript_span: null source_loss_log_path: null

Specialty Pharma Gross-to-Net Ratio Creates ~50% Hidden Revenue Haircut vs. Prescription Volume

In specialty pharma, publicly reported prescription volume data (IMS/Symphony weekly Rx counts) systematically overstates net revenue by the gross-to-net discount rate — typically 40-60% for branded products. Rebates, co-pay assistance programs, specialty pharmacy fees, and chargebacks consume half of gross revenue before anything reaches the income statement. Investors who track "Rx growth = revenue growth" will consistently over-model net revenue. The structural check is net revenue per prescription: if this metric is stable or improving as volume scales, growth is genuinely demand-driven; if it's declining, payer mix or formulary degradation is silently compressing the economics.

Evidence

• ARQT ZORYVE: ~22,000 weekly Rxs (4-week rolling), but 50% GTN ratio means only ~$127.5M net product revenue in Q4 FY25 against a much larger gross prescription dollar value. Management confirmed 50% GTN as structural and unlikely to improve.
• Rx volume doubled YoY in FY2025; net revenue grew 123% — the ~23pp beat on volume suggests net revenue per Rx was stable-to-improving, validating demand quality and ruling out GTN degradation.
• Primary patient complaint is cost (co-pay assistance is essential), signaling the company is absorbing significant GTN friction to maintain prescription access.

Implication

When analyzing any specialty pharma: (1) Always obtain the gross-to-net ratio and apply it to external prescription volume data before modeling net revenue. (2) Track net revenue per Rx across quarters — deterioration is an early warning of payer pushback or formulary displacement. (3) Don't treat 91% gross margins in isolation; validate that the GTN haircut is stable, not expanding. A company can show high gross margins while the underlying GTN dynamics are quietly eroding unit economics.